Prospects for using the qrisk3 risk scale in patients with chronic kidney disease and sarcopenia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. Evaluation of the relationship between sarcopenia, chronic kidney disease (CKD) and the risk of cardiovascular events according to the QRISK3 scale.

Material and methods. The study involved 143 patients with CKD, including 40 with sarcopenia and 104 without sarcopenia. All patients had their skeletal muscle mass index calculated, muscle strength assessed, their SPPB score calculated and their risk assessed according to the QRISK3 scale. For statistical analysis of the data obtained, the R language, RStudio software, with the following packages were used: tidyverse, gt, modelsummary, ggplot2. At a significance level (p) of less than 0.05, the null hypothesis (H0) was rejected, and changes between the groups were considered reliable.

Results. Patients with sarcopenia had a higher probability of developing cardiovascular diseases, according to the QRISK3 scale. Patients with sarcopenia had higher strength index, strength and skeletal muscle mass index, and lower body mass index compared to patients without sarcopenia. Glomerular filtration rate (SFR) and physical fitness, expressed as points on the SPPB scale, were found to have a significant effect on QRISK3. In patients with sarcopenia, a stronger relationship between age and QRISK3 was observed. An increase in SFR by 1 ml/min/1,73 m² was associated with a decrease in QRISK3 by 0,49%, and the presence of sarcopenia and male gender strengthened this relationship.

Conclusion. The obtained results indicate that kidney function and sarcopenia can significantly affect the assessment of cardiovascular risk according to the QRISK3 scale.

Full Text

Restricted Access

About the authors

Anna V. Sokolova

Pirogov Russian National Research Medical University; Research Institute for Healthcare Organization and Medical Management

Author for correspondence.
Email: sokolova2211@gmail.com

PhD in Medicine, Associate Professor, Associate Professor at the Department of Propaedeutics of Internal Diseases No. 1, Institute of Clinical Medicine

Russian Federation, 1 Ostrovityanova St., Moscow, 117513; Moscow

Elena A. Stafeeva

Pirogov Russian National Research Medical University

Email: alena.stafeeva16@yandex.ru

PhD in Medicine, Teaching Assistant at the Department of Propaedeutics of Internal Medicine No. 1, Institute of Clinical Medicine

Russian Federation, 1 Ostrovityanova St., Moscow, 117513

Aleksandr N. Stafeev

Sechenov First Moscow State Medical University (Sechenov University)

Email: i@stafeev-pro.ru

Teaching Assistant at the Department of Hospital Therapy No. 2

Russian Federation, Bldg. 2, 8 Trubetskaya St., Moscow, 119048

Dmitry O. Dragunov

Pirogov Russian National Research Medical University; Research Institute for Healthcare Organization and Medical Management

Email: tamops2211@gmail.com

PhD in Medicine, Associate Professor, Associate Professor at the Department of Propaedeutics of Internal Diseases No. 1, Institute of Clinical Medicine

Russian Federation, 1 Ostrovityanova St., Moscow, 117513; Moscow

Grigory P. Arutyunov

Pirogov Russian National Research Medical University

Email: arutyunov_gp@rsmu.ru

Dr.Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Director of the Institute of Clinical Medicine, Head of the Department of Propaedeutics of Internal Diseases No. 1, Institute of Clinical Medicine

Russian Federation, 1 Ostrovityanova St., Moscow, 117513

References

  1. Graham I.M., Di Angelantonio E., Visseren F., et al. European Society of Cardiology Cardiovascular Risk Collaboration. Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8. J. Am. Coll. Cardiol. 2021;77(24):3046–57. doi: 10.1016/j.jacc.2021.04.052. [PMID: 34140109, PMCID: PMC8091419].
  2. Gansevoort R.T., Correa-Rotter R., Hemmelgarn B.R., et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52. doi: 10.1016/S0140-6736(13)60595-4. [Epub 2013 May 310.qwa, PMID: 23727170].
  3. Li X., Lindholm B. Cardiovascular Risk Prediction in Chronic Kidney Disease. Am. J. Nephrol. 2022;53(10):730–9. doi: 10.1159/000528560. [Epub 2022 Dec 8, PMID: 36481730].
  4. Mok Y., Ballew S.H., Matsushita K. Chronic kidney disease measures for cardiovascular risk prediction. Atherosclerosis. 2021;335:110–8. doi: 10.1016/j.atherosclerosis.2021.09.007. [Epub 2021 Sep 9, PMID: 34556333].
  5. Jankowski J., Floege J., Fliser D., et al. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157–72. doi: 10.1161/CIRCULATIONAHA.120.050686. [Epub 2021 Mar 15, PMID: 33720773, PMCID: PMC7969169].
  6. Castillo E.M., Goodman-Gruen D., Kritz-Silverstein D., et al. Sarcopenia in elderly men and women: the Rancho Bernardo study. Am. J. Prev. Med. 2003;25(3):226–31.
  7. Гасанов М.З. Саркопения у пациентов с хронической болезнью почек: распространенность, особенности патогенеза и клиническое значение. Нефрология. 2021;25(1):47–58. doi: 10.36485/1561-6274-2021-25-1-47-58.
  8. Wilkinson T.J., Miksza J., Yates T., et al. Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: a UK Biobank study. J Cachexia Sarcopen Muscle. 2021;12(3):586–98. doi: 10.1002/jcsm.12705.
  9. Cruz-Jentoft A.J., Bahat G., Bauer J., et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. [PMID: 30312372, PMCID: PMC 6322506].
  10. Kidney International Supplements. KDIGO 2019;48(4):601. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. ScienceDirect.com [Electronic resource]. URL: https://www.sciencedirect.com/journal/kidneyinternational-supplements/vol/3/issue/1.
  11. Hippisley-Cox J., Coupland C., Vinogradova Y., et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136. doi: 10.1136/bmj.39261.471806.55. [Epub 2007 Jul 5, PMID: 17615182, PMCID: PMC1925200].
  12. Hippisley-Cox J., Coupland C., Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. doi: 10.1136/bmj.j2099. [PMID: 28536104, PMCID: PMC5441081].
  13. Hippisley-Cox J., Coupland C.A.C., Bafadhel M., et al. Development and validation of a new algorithm for improved cardiovascular risk prediction. Nat. Med. 2024;30(5):1440–7. doi: 10.1038/s41591-024-02905-y. [Epub 2024 Apr 18, PMID: 38637635, PMCID: PMC11108771].
  14. Damluji A.A., Alfaraidhy M., AlHajri N., et al. Sarcopenia and Cardiovascular Diseases. Circulation. 2023;147(20):1534–53. doi: 10.1161/CIRCULATIONAHA.123.064071. [Epub 2023 May 15, PMID: 37186680, PMCID: PMC10180053].
  15. Okamura H., Kimura N., Mieno M., et al. Preoperative sarcopenia is associated with late mortality after off-pump coronary artery bypass grafting. Eur. J. Cardiothorac. Surg. 2020;58(1):121–9. doi: 10.1093/ejcts/ezz378. [PMID: 31995164].
  16. Pizzimenti M., Meyer A., Charles A.L., et al. Sarcopenia and peripheral arterial disease: a systematic review. J. Cachexia Sarcopenia Muscle. 2020;11(4):866–86. doi: 10.1002/jcsm.12587. [Epub 2020 Jul 10, PMID: 32648665, PMCID: PMC7432591].
  17. Voulgaridou G., Tyrovolas S., Detopoulou P., et al. Diagnostic Criteria and Measurement Techniques of Sarcopenia: A Critical Evaluation of the Up-to-Date Evidence. Nutrients. 2024;16(3):436. Published 2024 Feb 1. doi: 10.3390/nu16030436.
  18. Kara M., Kaymak B., Frontera W., et al. Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM. J. Rehabil. Med. 2021;53(6):jrm00209. Published 2021 Jun 21. doi: 10.2340/16501977-2851.
  19. Zhang Y., Guo J.Y., Wang F., et al. Start with muscle mass or muscle strength in diagnosis and management of sarcopenia? A systematic review of guidance documents. Asia Pac. J. Clin. Nutr. 2024;33(2):247–71. doi: 10.6133/apjcn.202406_33(2).0011.
  20. Соколова А.В., Драгунов Д.О., Арутюнов Г.П., Митрохин В.М. Прогностическое значение саркопении у пациентов с ХБП. Клиническая нефрология. 2019;1:48–55. [20. Sokolova A.V., Dragunov D.O., Arutyunov G.P., Mitrokhin V.M. Prognostic value of sarcopenia in patients with CKD. Clinical nephrology. 2019;1:48–55 (In Russ.)].
  21. Соколова А.В, Драгунов Д.О., Арутюнов Г.П. Скрининг на саркопению у пациентов с хронической сердечной недостаточностью и хронической болезнью почек. Клиническая нефрология. 2024;16(1):25–29. [21. Sokolova A.V., Dragunov D.O., Arutyunov G.P. Screening for sarcopenia in patients with chronic heart failure and chronic kidney disease. Clinical nephrology. 2024;16(1):25–29 (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. QRІЅK3 in patients depending on the presence of sarcopenia

Download (19KB)
Indexing metadata
3. Fig. 2. QRISK3 and age relationship in patients depending on the presence of sarcopenia

Download (15KB)
Indexing metadata
4. Fig. 3. Relationship between SCF and QRISK3 in patients depending on the presence of sarcopenia and gender

Download (27KB)
Indexing metadata